Congratulations to Dr. Thibaut Reverdy, a medical oncologist at the Hospices Civils de Lyon (HCL), on winning the Young Researcher Award at the International Symposium on Public and Patient Engagement in Cancer Research in Marseille.
This award recognizes work conducted with One2Treat Voice, an approach designed to better incorporate the preferences of various stakeholders into the design of clinical trials. As part of a therapeutic de-escalation trial for endometrial cancer, the team explored how clinicians and patients prioritize the various outcomes and goals of a treatment.
The results highlight significant differences in priorities. While clinicians consider the prevention of recurrence to be the most important criterion, patients place a central emphasis on quality of life. Treatment toxicity and cost rank third and fourth, respectively. The study also showed that a 10% improvement in quality of life was perceived as clinically significant.
This research highlights a fundamental reality: what matters most to patients is not always what clinicians instinctively prioritize. Gaining a better understanding of these preferences even before a clinical trial begins can help in selecting more relevant endpoints and designing studies that are more focused on the expectations of those affected by the disease.
Beyond identifying relevant outcome measures, this approach also paves the way for new ways to assess clinical benefit. By combining the preferences expressed by stakeholders with statistical approaches such as Generalized Pairwise Comparisons (GPC) and Net Treatment Benefit (NTB)—notably developed by Dr. Julien Péron—it becomes possible to incorporate patients’ priorities into the very design of clinical trials.
This recognition highlights Dr. Reverdy’s commitment to more participatory clinical research and helps advance the integration of patient preferences into the development of future treatments.
